Psychodermatology: an update.
It has been estimated that in at least one third of dermatology patients, effective management of the skin disorder involves consideration of associated emotional factors. This article provides an overview of psychodermatology with a focus on the more recent literature and an emphasis on the clinical aspects and psychologic therapies for (1) cutaneous associations of psychiatric disorders and (2) psychiatric associations of certain cutaneous disorders that are known to be influenced by psychosomatic factors. This article also provides an update on the use of psychotropic drugs (i.e., the antianxiety, antidepressant, and antipsychotic agents) for the treatment of mental disorders that occur in conjunction with cutaneous conditions. Some of their other pharmacologic properties, such as the antihistaminic and analgesic effects of some antidepressant agents are also reviewed.
Gupta
M A
MA
Department of Psychiatry, University of Western Ontario, London, Canada.
Gupta
A K
AK
D000700:Analgesics / Q000627:therapeutic use; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D004644:Emotions; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D001523:Mental Disorders / Q000150:complications / Q000188:drug therapy; D011602:Psychophysiologic Disorders / Q000188:drug therapy*; D011613:Psychotherapy; D011619:Psychotropic Drugs / Q000627:therapeutic use; D012871:Skin Diseases / Q000188:drug therapy / Q000523:psychology*
D000700:Analgesics; D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D006634:Histamine H1 Antagonists; D011619:Psychotropic Drugs